Comparing Patient-adjusted Versus Physician-adjusted Titration of BIAsp 30 Combined With Metformin in Type 2 Diabetes Patients
A 20-week Study Comparing Patient-adjusted Versus Physician-adjusted Titration of BIAsp 30 Combined With Metformin in Type 2 Diabetes Patients Uncontrolled on NPH Insulin
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Alexandria, Egypt, 21131
- Novo Nordisk Investigational Site
-
Beni-Suef, Egypt, 62511
- Novo Nordisk Investigational Site
-
Cairo, Egypt, 11562
- Novo Nordisk Investigational Site
-
-
-
-
-
Bandung, Indonesia, 40161
- Novo Nordisk Investigational Site
-
Malang, Indonesia, 65111
- Novo Nordisk Investigational Site
-
-
-
-
-
Casablanca, Morocco, 20100
- Novo Nordisk Investigational Site
-
Marrakech, Morocco, 40000
- Novo Nordisk Investigational Site
-
-
-
-
-
Jeddah, Saudi Arabia, 80215
- Novo Nordisk Investigational Site
-
Riyadh, Saudi Arabia, 11211
- Novo Nordisk Investigational Site
-
Riyadh, Saudi Arabia, 11426
- Novo Nordisk Investigational Site
-
Taif, Saudi Arabia, 21944
- Novo Nordisk Investigational Site
-
-
-
-
-
Tunis, Tunisia, 1007
- Novo Nordisk Investigational Site
-
Tunis, Tunisia, 1008
- Novo Nordisk Investigational Site
-
-
-
-
-
Ha Noi City, Vietnam
- Novo Nordisk Investigational Site
-
Ho Chi Minh City, Vietnam
- Novo Nordisk Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnosed with type 2 diabetes for a minimum of 12 months prior to screening
- Currently treated with a NPH insulin for at least 3 months prior to screening
- Stable treatment (no change in dose or regimen) with a total daily dose of at least 1500 mg metformin or maximum tolerated dose (minimum 1000 mg) ± additional OAD treatment. The metformin treatment must have been stable for at least 2 months prior to screening
- HbA1c between 7.0% and 10.0% (both inclusive). (One re-test within one week of screening visit is allowed. The last sample will be conclusive.)
- Body Mass Index (BMI) below or equal to 40.0 kg/m^2
- Able and willing to eat at least 2 main meals each day during the trial
- Able and willing to adhere to the protocol including compliance with performance of self measured plasma glucose (SMPG), injection regimen and titrating themselves according to the protocol
- Experience in performing self-measured plasma glucose (SMPG)
Exclusion Criteria:
- Treatment with any thiazolidinedione (TZD) and Glucagon-like peptide-1 (GLP-1) receptor agonists or pramlintide within the last 3 months prior to screening
- Impaired hepatic function defined as alanine aminotransferase (ALAT) above or equal to 2.5 times upper referenced limit. (One re-test within one week of screening visit is allowed. The last sample will be conclusive.)
- Impaired kidney function with serum creatinine above or equal to 133 µmol/L (1.5 mg/dL) for males and above or equal to 124 µmol/L (1.4 mg/dL) for females. (One re-test within one week of screening visit is allowed. The last sample will be conclusive.)
- Cardiac problems or uncontrolled treated/untreated severe hypertension (defined as systolic blood pressure above or equal to 180 mmHg and/or diastolic blood pressure above or equal to 100 mmHg)
- Previous use of pre-mixed insulin products (pre-mixed insulin analogues or pre-mixed human preparations)
- Recurrent severe hypoglycaemia (more than 1 severe hypoglycaemic episode, during the last 12 months) or hypoglycaemic unawareness as judged by the Investigator or hospitalisation for diabetic ketoacidosis during the previous 6 months
- Known proliferative retinopathy or maculopathy requiring treatment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Subject-driven titration
|
Dose individually adjusted by the subjects themselves according to the titration algorithm every second week.
Administered subcutaneously (s.c., under the skin) twice daily.
Dose individually adjusted according to the directions given by the investigator.
Administered subcutaneously (s.c., under the skin) twice daily.
|
|
Experimental: Investigator-driven titration
|
Dose individually adjusted by the subjects themselves according to the titration algorithm every second week.
Administered subcutaneously (s.c., under the skin) twice daily.
Dose individually adjusted according to the directions given by the investigator.
Administered subcutaneously (s.c., under the skin) twice daily.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in HbA1c From Baseline
Time Frame: Week 0, week 20
|
Change in HbA1c (%) from baseline to the end of the treatment period.
|
Week 0, week 20
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Fasting Plasma Glucose (FPG) (Laboratory Values) From Baseline
Time Frame: Week 0, week 20
|
Change in FPG (laboratory values) from baseline to the end of the treatment period
|
Week 0, week 20
|
|
Number of Hypoglycaemic Episodes During the Trial From Baseline
Time Frame: Week 20
|
The number of hypoglycaemic episodes (a blood glucose level of approximately 2.8 mmol/L [50 mg/dL] or plasma glucose level 3.1 mmol/L [56 mg/dL]) during the trial.
|
Week 20
|
|
Change in Patient Reported Outcomes: Treatment-Related Impact Measures for Diabetes (TRIM-D)
Time Frame: Week 0, week 20
|
Mean change from baseline in Treatment Related Impact Measure - Diabetes (TRIM-D) scores.
The score measured treatment satisfaction which included an overall score as well the subscale scores (daily life, diabetes management, compliance and psychological health).
The scores were transformed to a 0-100 scale with higher scores indicating a better health state.
|
Week 0, week 20
|
|
Change in Patient Reported Outcomes: Treatment-Related Impact Measures for Diabetes (TRIM-D)-Treatment Burden
Time Frame: Week 0, week 20
|
Mean change from baseline in Treatment Related Impact Measure - Diabetes (TRIM-D) scores.
The score measured treatment satisfaction which included a subscale score -treatment burden.
The scores were transformed to a 0-100 scale with higher scores indicating a better health state.
|
Week 0, week 20
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Glucose Metabolism Disorders
- Metabolic Diseases
- Endocrine System Diseases
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
- Hypoglycemic Agents
- Physiological Effects of Drugs
- Insulin
- Insulin, Globin Zinc
- Insulin Aspart
- Insulin, Long-Acting
- Insulin degludec, insulin aspart drug combination
- Biphasic Insulins
- Insulin aspart, insulin aspart protamine drug combination 30:70
- Insulin, Isophane
Other Study ID Numbers
Other Study ID Numbers
- BIASP-3968
- U1111-1125-7572 (Other Identifier: WHO)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.